September 2013, Vol 2, No 6

← Back to Issue

Illustrating the New Era of Personalized Medicine


Letter to Our Readers

Dear Colleague,

It gives us great pleasure to present this issue of Personalized Medicine in Oncology (PMO). Over the past several months, we have thoroughly examined every aspect of the journal – appearance, readability, and most importantly, editorial content.

You will see the result of our efforts in the following ways:

The immune system is back in the discussion of how to fight cancer. Many exciting new agents are being studied in clinical trials in diseases such as non–small cell lung cancer, melanoma, and kidney cancer, to name just a few. PMO will keep readers up to date on advances in this area and discuss what it means for patients.

Interview With the Innovators
The world of personalized medicine is a rapidly changing, ever-evolving state involving many stakeholders on the front lines of its creation: physicians, industry, researchers, patient advocates, and payers. PMO seeks out the leaders in these sectors and brings you their game-changing strategies, missions, and impact on personalized oncology care.

The Last Word
In this department, our Strategic Editor and Editor in Chief sum up thoughts on various overriding themes in the world of personalized medicine.

Journal Design
You will notice a redesign in the look of the entire journal. This new, streamlined design is intended to make the journal easier to read and navigate.

We believe these will greatly enhance your reading experience. Please let us know what you think! E-mail our Editorial Director, Kristin Siyahian at We look forward to and welcome your feedback.


Al Benson, MD
Editor in Chief
Personalized Medicine in Oncology

Uncategorized - September 23, 2013

Ponatinib Given Early May Stem Resistance in CML

Mutation analysis at baseline and at the end of treatment (EOT) provides information about the response to ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphocytic leukemia (ALL) enrolled in the phase 2 PACE study. Results were presented at the 2013 Annual Meeting of ASCO. [ Read More ]

The Last Word - September 23, 2013

To PARP or Not to PARP – What Is the Question? Perspective on the First “Disappointment” With a New Drug Class

The proposition appeared simple – as it turns out, deceptively so. The oncology community was a bit disheartened when the much anticipated results of a phase 3 trial by Dr Joyce O’Shaughnessy did not replicate the success of her phase 2 study1 in which the PARP inhibitor iniparib was used [ Read More ]